Review ArticleCancer and atrial fibrillation: Epidemiology, mechanisms, and anticoagulation treatment
Introduction
Advances in screening techniques and treatments have improved the survival of patients with cancer, as shown by data from the American Cancer Society and National Cancer Institute reporting that more than 16.9 million Americans with a history of cancer were alive on January 1, 2019 and this number is expected to increase to 22.1 million by January 2030.1 However, an increased risk of developing cardiovascular diseases (CVD) compared with non–cancer controls is becoming evident in these patients.2 The most common CVD are heart failure (HF), coronary artery disease (CAD), valvular and pericardial diseases, venous thromboembolic disease, peripheral vascular diseases and pulmonary hypertension. In addition, there is a wide spectrum of rhythm disorders that may complicate the clinical course of cancer patients, ranging from brady-arrhythmias and conduction defects to supraventricular arrhythmias and atrial fibrillation (AF).3 The onset of AF may be promoted by the presence of cancer4, 5, 6, 7 and by cancer treatments such as surgery, chemotherapy (CT) and radiotherapy (RT).3,8,9 Furthermore, common risk factors may predispose to both cancer and AF, as well as there may be common pathways driving both tumorigenesis and AF development, such as inflammation.3,8,9
Current guidelines on the management of patients with AF and cancer do not provide clear-cut recommendations on the optimal thrombo-prophylaxis strategy in these patients, especially those undergoing CT or RT.
The purpose of this review is to summarize the current evidence on the relationship between AF and cancer and to provide some practical insights about the use of anticoagulants in this setting.
Section snippets
Risk of AF in patients with cancer
Several studies have shown a 20% prevalence of AF in patients with cancer,4, 5, 6, 7 regardless of the type of cancer.6,10 The highest risk of developing new AF was found in the first three months after the diagnosis of cancer,7 with the risk progressively decreasing after 6 months.10 This early detection of AF may be due to a tighter clinical monitoring of these patients after cancer diagnosis.
In one study, new onset AF was associated with a higher risk of thromboembolism [adjusted Hazard
Risk of cancer in patients with AF
Previous studies showed an increased risk of developing cancer in patients with AF. Indeed, the incidence of cancer in AF patients was reported to be 30–40% higher than in the general population, with men being more likely to develop cancer than women.43 In a retrospective study performed by Hung et al.,43 which included 332,555 AF patients (55.2% were men) without past history of cancer and with a mean age of 70.8 ± 13.1 years, of whom 68.5% were affected by hypertension, 28.4% by diabetes,
Mechanisms linking AF and cancer
There are several mechanisms potentially linking AF and cancer (Fig. 1), including systemic inflammation which seems to represent a common milieu for these two conditions. Increased production of chemokines and cytokines, such as interleukins 1 and 6, and systemic acute phase proteins such as C-reactive protein (CRP), has been described in patients with cancer.50 In addition, inflammation markers, such as high white blood cells, CRP and ceruloplasmin (HR 1.039, 95%CI 1.007–1.072, p = 0.016, HR
Ischaemic and bleeding risk in patients with AF and malignancies
A nationwide database study performed on 533,044 patients with AF or atrial flutter showed an increased risk of death in patients who also had cancer (OR 1.81, 95%CI 1.78–1.85).65
Patients with cancer in the ROCKET AF trial had a higher rate of non-cardiovascular death (HR 1.47, 95%CI 1.04–2.07) compared with those without cancer, mainly due to causes related to cancer (HR 1.30, 95%CI 1.16–1.47).44 An even higher risk of death was reported in the ENGAGE AF-TIMI 48 trial,45 in which 1153 new
DOACs for treating patients with AF and cancer
As the presence of cancer may increase both ischemic and bleeding risk in patients with AF,67 the benefits and advantages of DOAC may be more evident in this subgroup of patients. The bulk of the evidence today supports using DOACs instead of VKA in most patients with AF and cancer.68 The safety and effectiveness of DOACs in the setting of cancer have been recently investigated. A post-hoc analysis from the ARISTOTLE study showed that, in patients with active cancer, compared with warfarin,
Factors affecting management of anticoagulation treatment in patients with AF and cancer
Several factors may affect the management of oral anticoagulation in patients diagnosed with AF and cancer, including 1) drug-drug interactions between oral anticoagulants and anticancer therapies, 2) patient-related characteristics (e.g., thrombocytopenia, liver damage), 3) the presence of other indications for anticoagulants (e.g., VTE, intracardiac thrombus, prosthetic heart valve) and 4) availability of reversal agent.
Management of oral anticoagulation in specific situations
The choice of anticoagulant may change according to cancer treatment, as LMWH, VKAs and DOACs have benefits and drawbacks that should be evaluated on an individual basis. Thus, the anticoagulation treatment may vary in patients undergoing CT, RT, or surgical interventions (Fig. 2). Independently from the type of cancer treatment, the eligibility of patients for DOACs should always be considered, as DOACs are associated with a lower rate of major and ICH compared to VKAs.
However, in patients
Conclusions and perspectives
In conclusion, there is an increased risk of developing AF in patients with cancer, which is particularly high in the first 3 months after the diagnosis of cancer, as a consequence of 1) increased detection of AF during the work-up of cancer, 2) a possible actual increase in AF incidence, perhaps due to systemic inflammation and 3) antineoplastic drugs that increase the risk of AF.
There still are some grey zones that will need further research in the field of oncology and AF. The frequencies of
Funding source
None.
Declaration of Competing Interest
None.
References (86)
- et al.
Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study)
Am J Cardiol
(2015) - et al.
Incident thromboembolism and heart failure associated with new-onset atrial fibrillation in cancer patients
Int J Cardiol
(2013) - et al.
Atrial fibrillation in cancer patients: hindsight, insight and foresight
Int J Cardiol
(2017) - et al.
Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database
Ann Thorac Surg
(2010) - et al.
Predictive value of preoperative tissue Doppler echocardiographic analysis for postoperative atrial fibrillation after pulmonary resection for lung cancer
J Thorac Cardiovasc Surg
(2010) - et al.
Incidence, predictors, and outcomes associated with postoperative atrial fibrillation after major noncardiac surgery
Am Heart J
(2012) - et al.
Drug-induced atrial fibrillation
J Am Coll Cardiol
(2004) - et al.
Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity
Ann Oncol
(2000) - et al.
Mechanism of cardiovascular toxicity by proteasome inhibitors: new paradigm derived from clinical and pre-clinical evidence
Eur J Pharmacol
(2018) - et al.
Rates and risk of atrial arrhythmias in patients treated with Ibrutinib compared with cytotoxic chemotherapy
Am J Cardiol
(2019)
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology
Semin Oncol
Ibrutinib displays atrial-specific toxicity in human stem cell-derived cardiomyocytes
Stem Cell Rep
Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium
Heart Rhythm
Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation
Redox Biol
The association between the use of non-steroidal anti-inflammatory drugs and atrial fibrillation: a nationwide case-control study
Int J Cardiol
Risk factors for new-onset atrial fibrillation: a focus on Asian populations
Int J Cardiol
Risk and predictors of subsequent cancers of patients with newly-diagnosed atrial fibrillation - a nationwide population-based study
Int J Cardiol
Risk-based lung cancer screening: a systematic review
Lung Cancer
Cancer-related inflammation and treatment effectiveness
Lancet Oncol
ROS signalling in the biology of cancer
Semin Cell Dev Biol
Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: guidance from the SSC of the ISTH
J Thromb Haemost
Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation
Blood Adv
Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial
J Thromb Haemost
Thrombocytopenia in cancer patients
Thromb Res
Antithrombotic medication in cancer-associated thrombocytopenia: current evidence and knowledge gaps
Crit Rev Oncol Hematol
Anticoagulant and antiplatelet treatment in cancer patients with thrombocytopenia
Thromb Res
Patterns of anticoagulation for atrial fibrillation in cancer patients referred to cardio-oncological evaluation
Eur J Intern Med
Cancer treatment and survivorship statistics, 2019
CA Cancer J Clin
Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study
J Clin Oncol
2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
Eur J Heart Fail
First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation
Intern Emerg Med
Risk of malignant cancer among women with new-onset atrial fibrillation
JAMA Cardiol
Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study
BMC Cancer
Atrial fibrillation after pulmonary lobectomy for lung cancer affects long-term survival in a prospective single-center study
J Cardiothorac Surg
Morbidity and mortality with atrial fibrillation following colorectal surgery
ANZ J Surg
Prevalence and predictors of new-onset atrial fibrillation after elective surgery for colorectal cancer
Pacing Clin Electrophysiol
Cardiovascular morbidity and mortality after treatment of hyperthyroidism with either radioactive iodine or thyroidectomy
Thyroid
Update on cardiotoxicity of anti-cancer treatments
Eur J Clin Invest
Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial
J Clin Oncol
2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)
Eur Heart J
The incidence of atrial fibrillation with trastuzumab treatment: a systematic review and meta-analysis
Cardiovasc Ther
Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity
Anticancer Drugs
Cisplatin-induced atrial fibrillation
J Clin Oncol
Cited by (23)
Long-term prognostic significance of history of cancer and atrial fibrillation in coronary artery disease
2023, IJC Heart and VasculatureUnderweight predicts poststroke cardiovascular events in patients without atrial fibrillation
2022, Journal of Stroke and Cerebrovascular DiseasesCitation Excerpt :However, it has not been understood how underweight increases stroke or systemic embolism in AF. It might be possible for systemic illness such as malignancy to cause underweight and generate AF with thrombosis.23 Moreover, while these increased risks for those who are underweight have been suggested in AF population who have not developed clinical cardiovascular diseases yet, there is no study on patients who have established cardiovascular diseases such as stroke with AF.
Optimizing antithrombotic therapy for atrial fibrillation in cancer
2022, Thrombosis ResearchCitation Excerpt :Dehydration, sepsis and drugs can worsen renal function in cancer patients and dose adjustments may be needed [65]. Close monitoring for bleeding signs/symptoms is also needed in patients with chronic liver failure [65]. In cancer patients the incidence of AF is increased.